scholarly journals A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study to Assess the Effects of Long-Term Opioid Drug Consumption and Subsequent Abstinence in Chronic Noncancer Pain Patients Receiving Controlled-Release Morphine

Pain Medicine ◽  
2005 ◽  
Vol 6 (2) ◽  
pp. 113-121 ◽  
Author(s):  
David T. Cowan ◽  
Dame Jenifer Wilson-Barnett ◽  
Peter Griffiths ◽  
David J. A. Vaughan ◽  
Anjalee Gondhia ◽  
...  
Keyword(s):  
Pilot Study ◽  
Controlled Release ◽  
Drug Consumption ◽  
Double Blind ◽  
Chronic Noncancer Pain ◽  
Double Blind Placebo ◽  
Noncancer Pain ◽  
Pain Patients

Assessing Cognitive and Psychomotor Performance Under Long-Term Treatment with Transdermal Buprenorphine in Chronic Noncancer Pain Patients

2007 ◽  
Vol 105 (5) ◽  
pp. 1442-1448 ◽  
Author(s):  
Oguzhan Dagtekin ◽  
Hans J. Gerbershagen ◽  
Werner Wagner ◽  
Frank Petzke ◽  
Lukas Radbruch ◽  
...  
Keyword(s):  
Psychomotor Performance ◽  
Term Treatment ◽  
Chronic Noncancer Pain ◽  
Long Term Treatment ◽  
Noncancer Pain ◽  
Pain Patients

scholarly journals Bupropion Reduces Some of the Symptoms of Marihuana Withdrawal in Chronic Marihuana Users: A Pilot Study

2012 ◽  
Vol 6 ◽  
pp. SART.S9706 ◽  
Author(s):  
David M. Penetar ◽  
Alison R. Looby ◽  
Elizabeth T. Ryan ◽  
Melissa A. Maywalt ◽  
Scott E. Lukas
Keyword(s):  
Pilot Study ◽  
Cognitive Performance ◽  
Treated Group ◽  
Withdrawal Symptoms ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Subject Retention

Bupropion's (Zyban® SR) effectiveness to treat symptoms experienced in marihuana withdrawal was tested in a double-blind, placebo-controlled study with chronic, heavy marihuana users. Participants maintained their usual marihuana intake until Quit Day after which they were required to cease intake of THC products for 14 days. A Withdrawal Discomfort Score revealed that for 7 days immediately following cessation, placebo-treated subjects reported more symptoms than bupropion-treated subjects. Self-reported craving for marihuana increased for the placebo-treated group but not for those treated with bupropion. Measures of sleep and cognitive performance were not different between the two groups. Participants in the bupropion treatment arm were more likely to complete the study than those randomized to the placebo arm (50% completion for bupropion vs. 33% completion for placebo). These results suggest that bupropion may be useful for alleviating marihuana withdrawal symptoms and be useful in subject retention during long-term cessation programs.

A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure

2007 ◽  
Vol 153 (5) ◽  
pp. 868-873 ◽  
Author(s):  
Stephen S. Gottlieb ◽  
Willem J. Kop ◽  
Sue A. Thomas ◽  
Scott Katzen ◽  
Mark R. Vesely ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Pilot Study ◽  
Controlled Release ◽  
Chronic Heart Failure ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document